Introduction: The Growing Need for Next-Generation Metabolic Biomarkers in Diabetes Care

Diabetes mellitus currently affects more than 537 million adults worldwide, with projections indicating a continued rise to 783 million by 2045. The metabolic complexity of diabetes extends well beyond simple hyperglycemia, encompassing disturbances in lipid metabolism, bile acid homeostasis, energy expenditure, and interorgan communication. Traditional clinical markers — fasting plasma glucose, hemoglobin A1c, and standard lipid panels — remain essential tools but provide an incomplete picture of the underlying pathophysiological processes driving disease progression and complication risk. Hemoglobin A1c, while invaluable for assessing average glycemic control over two to three months, does not capture acute metabolic fluctuations or reflect the function of specific organ systems involved in glucose regulation. Lipid profiles indicate cardiovascular risk but overlook hepatic steatosis and bile acid metabolism. These gaps highlight the urgent need for biomarkers that integrate signals from multiple metabolic axes. Fibroblast growth factor 19 (FGF19), an enterokine produced in the ileum in response to bile acid absorption, has attracted considerable attention as a biomarker that bridges intestinal function, hepatic metabolism, and systemic insulin sensitivity. This article provides an expanded examination of serum FGF19 as a biomarker for metabolic regulation in diabetes, integrating molecular mechanisms, clinical evidence across diverse populations, comparisons with established markers, and practical considerations for clinical implementation.

Molecular Foundations of FGF19 Biology

Biosynthesis and Regulation of FGF19 Expression

FGF19 belongs to the endocrine subfamily of fibroblast growth factors, which also includes FGF21 and FGF23. Unlike paracrine FGFs that require heparan sulfate for receptor binding, endocrine FGFs utilize Klotho coreceptors to achieve tissue-specific signaling. FGF19 is synthesized predominantly in ileal enterocytes, where its transcription is tightly regulated by the farnesoid X receptor (FXR), a nuclear receptor activated by bile acids. After meal ingestion, bile acids released into the intestinal lumen are absorbed in the terminal ileum, activate FXR, and induce FGF19 expression. The protein is then secreted into the portal circulation and reaches the liver, where it binds to a receptor complex composed of fibroblast growth factor receptor 4 (FGFR4) and the coreceptor β-Klotho. This binding initiates a signaling cascade that suppresses cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in the classic bile acid synthesis pathway, thereby creating a negative feedback loop that controls bile acid pool size. Beyond the liver, FGF19 receptors are expressed in adipose tissue, skeletal muscle, and the central nervous system, enabling systemic metabolic effects.

Metabolic Actions Across Tissues

The metabolic functions of FGF19 extend well beyond bile acid regulation. In the liver, FGF19 signaling inhibits gluconeogenesis by downregulating phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, while simultaneously stimulating glycogen synthesis through activation of glycogen synthase kinase-3β inactivation. These effects improve hepatic insulin sensitivity and reduce glucose output. In adipose tissue, FGF19 promotes fatty acid oxidation and enhances thermogenesis by inducing uncoupling protein 1 expression in brown adipose tissue and promoting the browning of white adipose tissue. Skeletal muscle responds to FGF19 by increasing glucose uptake and fatty acid oxidation, contributing to improved whole-body insulin sensitivity. Additionally, FGF19 acts on the brain to regulate feeding behavior and energy expenditure, with animal studies demonstrating that central FGF19 administration reduces food intake and increases energy expenditure. This multisystem metabolic profile positions FGF19 as an integrator of nutrient signals and a regulator of energy balance.

FGF19 Signaling Pathways and Cross-Talk with Other Metabolic Regulators

The intracellular signaling pathways activated by FGF19 involve the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade, which mediates transcriptional regulation of metabolic genes. FGF19 signaling also interacts with the insulin signaling pathway at multiple nodes, including Akt activation and forkhead box O1 inhibition. Recent evidence indicates that FGF19 can activate signal transducer and activator of transcription 3 (STAT3), which contributes to its anti-inflammatory effects in hepatocytes. Cross-talk with other endocrine FGFs, particularly FGF21, adds another layer of complexity. While both FGF19 and FGF21 improve insulin sensitivity and lipid metabolism, they are regulated by different nutritional signals and exhibit distinct tissue-specific actions. Understanding these interactions is important for interpreting serum FGF19 levels in the context of overall metabolic health.

Serum FGF19 in Diabetes: A Comprehensive Review of Clinical Evidence

Reduced FGF19 Levels in Type 2 Diabetes

Multiple cross-sectional and case-control studies have consistently demonstrated that serum FGF19 concentrations are significantly lower in individuals with type 2 diabetes (T2D) compared to normoglycemic controls. A meta-analysis incorporating data from 12 independent studies involving 2,847 participants reported a weighted mean difference of −32 pg/mL (95% CI: −47 to −17 pg/mL), with moderate heterogeneity across studies. The reduction in FGF19 appears to correlate with the severity of hyperglycemia and insulin resistance, with more pronounced deficits observed in patients with poorly controlled diabetes. Factors contributing to these reduced levels may include impaired FXR signaling in the ileum due to altered gut microbiota composition, reduced bile acid pool size, or intestinal epithelial dysfunction associated with diabetes. Importantly, some studies have reported that FGF19 levels are inversely correlated with fasting glucose and hemoglobin A1c, even after adjusting for age, sex, and body mass index, suggesting an independent association.

The relationship between FGF19 and insulin resistance has been examined using multiple measurement approaches, including the homeostatic model assessment for insulin resistance (HOMA-IR), the quantitative insulin sensitivity check index (QUICKI), and hyperinsulinemic-euglycemic clamp studies. In diabetic cohorts, lower FGF19 levels are consistently associated with higher HOMA-IR scores and reduced glucose disposal rates during clamp studies. A 2022 study of 320 patients with T2D found that each 10 pg/mL decrease in FGF19 was associated with a 0.15-unit increase in HOMA-IR (95% CI: 0.08–0.22) after multivariable adjustment. The mechanistic basis for this association likely involves reduced FGF19-mediated suppression of hepatic gluconeogenesis and impaired FGF19 stimulation of peripheral glucose uptake. Additionally, FGF19 deficiency may contribute to insulin resistance through increased bile acid toxicity and endoplasmic reticulum stress in hepatocytes. Beyond T2D, studies in individuals with prediabetes have shown that low FGF19 levels predict progression to overt diabetes. A 2023 prospective cohort study of 450 adults with impaired glucose tolerance reported that baseline FGF19 levels in the lowest quartile were associated with a 2.1-fold increased risk of progressing to T2D over 5 years (95% CI: 1.3–3.4) after adjusting for age, BMI, and fasting glucose.

FGF19 and Beta-Cell Function

Emerging evidence indicates that FGF19 may also serve as a marker of pancreatic beta-cell health. Several cross-sectional studies have reported positive correlations between serum FGF19 and indices of beta-cell function, including HOMA-β and the disposition index derived from oral glucose tolerance tests. Experimental data support these clinical observations: FGF19 receptor signaling in pancreatic islets enhances glucose-stimulated insulin secretion and promotes beta-cell survival under conditions of glucolipotoxicity. In a cohort of 185 patients with new-onset T2D, those with FGF19 levels above the median had significantly higher C-peptide responses to mixed meal stimulation, suggesting preserved beta-cell functional capacity. These findings raise the possibility that FGF19 assessment could help identify individuals at risk for progressive beta-cell decline, potentially guiding early intervention strategies.

Association with Non-Alcoholic Fatty Liver Disease and Hepatic Steatosis

Non-alcoholic fatty liver disease (NAFLD) affects an estimated 55–70% of individuals with T2D, representing a major source of liver-related morbidity. Reduced circulating FGF19 has been independently associated with increased hepatic fat content, steatosis severity, and elevated liver enzymes. In a study of 280 patients with biopsy-confirmed NAFLD, those with FGF19 concentrations below the median had significantly higher rates of non-alcoholic steatohepatitis (NASH) and advanced fibrosis (stage ≥2) after adjusting for age, BMI, and diabetes status. The odds ratio for NASH in the low FGF19 group was 2.4 (95% CI: 1.5–3.8). Mechanistically, FGF19 deficiency may promote hepatic steatosis by reducing bile acid synthesis, which affects lipid absorption and metabolism, and by impairing fatty acid oxidation. The inverse relationship between FGF19 and intrahepatic triglyceride content, measured by proton magnetic resonance spectroscopy, has been confirmed in multiple cohorts. Serum FGF19 measurement may therefore complement existing non-invasive markers such as the NAFLD fibrosis score and FibroScan for stratifying liver disease risk in diabetic patients.

FGF19 and Diabetes Complications

Beyond glycemic control and hepatic disease, FGF19 levels may predict the development of diabetic complications. A prospective study involving 800 patients with T2D followed for a median of 10 years found that those in the lowest FGF19 tertile had significantly higher risks of incident nephropathy (hazard ratio 2.3, 95% CI: 1.5–3.5) and cardiovascular events (hazard ratio 1.8, 95% CI: 1.2–2.7) after adjustment for conventional risk factors including HbA1c, blood pressure, and LDL cholesterol. These associations suggest that FGF19 captures aspects of metabolic risk not fully reflected by traditional markers. The relationship between low FGF19 and nephropathy may involve increased renal bile acid exposure and activation of fibrotic pathways, while the cardiovascular association could be mediated by effects on lipid metabolism and vascular inflammation. Retinopathy risk, however, has not been consistently linked to FGF19 levels in available studies, and more research is needed to clarify the specificity of these associations.

Comparative Analysis: FGF19 Relative to Established Metabolic Biomarkers

The clinical utility of any new biomarker must be evaluated against existing tools to determine its added value. Hemoglobin A1c remains the cornerstone of glycemic assessment, providing a reliable measure of average glucose over 2–3 months. However, A1c does not reflect acute metabolic changes, postprandial excursions, or the specific contributions of hepatic versus peripheral insulin resistance. FGF19, by contrast, responds dynamically to nutritional and pharmacological interventions and integrates information from the gut-liver axis. Fructosamine and glycated albumin offer shorter-term glycemic windows but lack organ-specific information. Adiponectin, an adipokine with insulin-sensitizing properties, is often reduced in obesity and T2D but primarily reflects adipose tissue function and does not capture hepatic bile acid metabolism. In a head-to-head comparison of 150 patients with T2D, FGF19 demonstrated a stronger correlation with HOMA-IR (r = −0.54) than adiponectin (r = −0.31) or leptin (r = 0.18). C-reactive protein, a marker of inflammation, provides complementary but distinct information and does not directly assess bile acid signaling. The most promising role for FGF19 may be as part of a multi-biomarker panel that includes FGF21, bile acids, and standard metabolic markers, potentially yielding composite scores with higher predictive accuracy for disease progression and treatment response.

Clinical Applications: Translating FGF19 Measurement into Practice

Monitoring Pharmacological Interventions

Several glucose-lowering agents have been shown to modulate FGF19 levels, and serial measurement could provide pharmacodynamic insight. Metformin, the first-line therapy for T2D, increases serum FGF19 in both diabetic and non-diabetic individuals, with effects observed within weeks of treatment initiation. The mechanism likely involves AMPK-mediated enhancement of FXR signaling in the ileum. GLP-1 receptor agonists, including liraglutide and semaglutide, also elevate FGF19 levels, an effect that may contribute to their weight-lowering and hepatoprotective actions. In a randomized trial of 120 patients with T2D and NAFLD, liraglutide treatment for 26 weeks increased FGF19 by a mean of 28 pg/mL, and the magnitude of increase correlated with reductions in liver fat content. Sodium-glucose cotransporter 2 inhibitors have shown variable effects on FGF19, with some studies reporting modest increases and others finding no significant change. Thiazolidinediones, by contrast, have been associated with reduced FGF19 levels, possibly through PPARγ-dependent effects on FXR expression. Baseline FGF19 measurement could help identify patients most likely to benefit from specific therapies, while monitoring changes could guide dose adjustments or treatment switches.

Risk Stratification for Disease Progression

The ability to predict which individuals with prediabetes or early diabetes will progress to more advanced disease or develop complications is a priority for personalized medicine. A longitudinal study of 450 prediabetic adults found that baseline FGF19 levels predicted progression to overt diabetes over 5 years, with an odds ratio of 0.78 per 10 pg/mL increase after adjusting for age, BMI, and fasting glucose. In established T2D, low FGF19 has been associated with higher risk of NAFLD progression, nephropathy, and cardiovascular events. A practical approach might involve establishing FGF19 thresholds — for example, values below 80 pg/mL could trigger more intensive monitoring of liver health and renal function, while values above 150 pg/mL might indicate lower complication risk. These thresholds require validation in diverse populations before clinical adoption. Integrating FGF19 into risk calculators alongside standard clinical variables could enhance their discriminative ability and clinical utility.

Therapeutic Targeting of the FGF19 Pathway

The recognition that FGF19 deficiency contributes to metabolic dysfunction has stimulated the development of FGF19 analogs and FXR agonists for therapeutic use. An engineered FGF19 variant, M70 (also known as NGM282 or aldafermin), has been evaluated in phase 2 trials for NAFLD and T2D. In a randomized, placebo-controlled trial involving 180 patients with T2D and NAFLD, M70 treatment for 12 weeks resulted in a 38% reduction in liver fat content measured by MRI-PDFF, along with significant improvements in insulin sensitivity and reductions in HbA1c compared to placebo. Importantly, the engineered FGF19 variant was designed to avoid the tumorigenic potential associated with wild-type FGF19 signaling through FGFR4 in the liver, and no concerning safety signals were observed in the trial. FXR agonists such as obeticholic acid, which increase endogenous FGF19 production, have also shown efficacy in NAFLD but are associated with pruritus and LDL cholesterol elevation. Direct FGF19 administration offers the advantage of bypassing FXR activation, potentially achieving beneficial metabolic effects with fewer off-target effects. Larger and longer-term studies are needed to confirm the safety, tolerability, and efficacy of FGF19-based therapies.

Methodological Considerations for FGF19 Measurement

Assay Methods and Standardization

Serum FGF19 is most commonly measured using commercial enzyme-linked immunosorbent assays (ELISAs), which offer reasonable sensitivity and throughput for research and clinical settings. However, assay variability across manufacturers and lots, lack of uniform calibration standards, and inter-laboratory differences have hindered the establishment of universal reference ranges. More recently, liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods have been developed, offering improved specificity and the ability to measure multiple analytes simultaneously. Reported fasting FGF19 levels in healthy adults typically range from 50 to 300 pg/mL, with considerable variation depending on the assay used, population characteristics, and sample handling protocols. A diurnal rhythm has been described, with levels peaking approximately 60–90 minutes after meal ingestion and reaching a nadir during fasting. For reliable clinical use, standardized pre-analytical protocols must be established, including requirements for fasting duration, time of day for sampling, and specimen processing temperature. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) has initiated efforts to develop a certified reference material for FGF19, which should improve inter-assay comparability and facilitate clinical implementation.

Factors Influencing FGF19 Levels

Clinicians and researchers must be aware of physiological and pathological factors that can influence FGF19 levels independently of diabetes status. Obesity is associated with reduced FGF19, and weight loss — whether through diet, exercise, or bariatric surgery — increases circulating levels. Dietary fat intake, particularly saturated fat, can modulate FXR activity and FGF19 secretion. Gallbladder function and bile acid dynamics also affect FGF19: individuals with gallstones or after cholecystectomy may have altered FGF19 levels. Genetic polymorphisms in the FGF19 gene and its receptor FGFR4 have been described, and certain variants are associated with altered metabolic phenotypes. Hepatic impairment, including cirrhosis, reduces FGF19 clearance and can elevate circulating levels, complicating interpretation in patients with advanced liver disease. Renal function also affects FGF19 levels, with chronic kidney disease associated with increased concentrations due to reduced renal clearance. These confounders must be carefully considered when interpreting FGF19 measurements in clinical practice.

Limitations of Current Evidence and Research Gaps

Despite the growing body of evidence supporting FGF19 as a metabolic biomarker, significant limitations must be acknowledged. The majority of published studies are cross-sectional or case-control in design, which restricts causal inference and cannot establish whether low FGF19 is a cause or consequence of metabolic dysfunction. Prospective studies with repeated measurements are needed to clarify temporal relationships. Sample sizes in many studies are moderate, and the populations studied are predominantly of European or East Asian ancestry, raising questions about generalizability to other ethnic groups. The influence of medications on FGF19 levels is incompletely characterized, and many studies do not adequately adjust for medication use. The optimal timing of FGF19 measurement relative to meals is not standardized, and the lack of established clinical cut-points limits practical application. Furthermore, the relationship between FGF19 and specific diabetes complications, particularly neuropathy and retinopathy, remains poorly understood. Large-scale, multi-ethnic prospective studies with standardized measurement protocols are urgently needed to address these gaps and move the field toward clinical implementation.

Future Directions: Integrating FGF19 into Precision Diabetes Care

The integration of FGF19 into routine clinical practice will require several advances. First, high-throughput, cost-effective assays with standardized reference ranges must become widely available. Second, prospective trials should define clinically meaningful FGF19 thresholds for identifying low-risk versus high-risk individuals, and these thresholds should be validated in diverse populations. Third, combining FGF19 with other biomarkers — including FGF21, total and individual bile acids, C-peptide, and markers of hepatic function — could yield composite scores with greater predictive accuracy than any single marker. Machine learning algorithms that integrate FGF19 with clinical variables, continuous glucose monitoring data, and multi-omics profiles could enable the development of personalized risk prediction models and treatment selection tools. Finally, the continued development of FGF19-based therapeutics, including engineered analogs and selective FXR modulators, holds promise for directly addressing the underlying metabolic deficiencies identified by low FGF19 levels. As understanding of the gut-liver axis and interorgan metabolic communication deepens, FGF19 stands as a compelling example of how a single molecule can integrate diverse physiological signals and inform both assessment and treatment of metabolic disease.

Conclusion

Serum fibroblast growth factor 19 represents a promising biomarker for metabolic regulation in diabetes, reflecting cross-talk between the intestine, liver, adipose tissue, and skeletal muscle. The consistent finding of reduced FGF19 levels in individuals with type 2 diabetes, along with associations with insulin resistance, beta-cell dysfunction, NAFLD, and long-term complication risk, positions FGF19 as a valuable addition to the metabolic biomarker armamentarium. While challenges related to assay standardization, confounding factors, and limited prospective data must be addressed before widespread clinical adoption, the potential benefits are substantial. FGF19 measurement could enhance risk stratification, guide therapy selection, and provide insight into the metabolic status of individual patients. Clinicians should remain aware of emerging evidence in this rapidly evolving field, while researchers should prioritize the large-scale, well-designed studies needed to translate FGF19 from a promising biomarker into a practical clinical tool.

Further Reading and Resources